Literature DB >> 14550760

A model to estimate the oestrogen receptor mediated effects from exposure to soy isoflavones in food.

Bob Safford1, Andrea Dickens, Nadine Halleron, David Briggs, Philip Carthew, Valerie Baker.   

Abstract

The advantages that regular consumption of a diet containing soy may have on human health have been enshrined in a major health claim that has been approved by the Food and Drug Administration in the USA, regarding potential protection from heart disease by soy. This could have a major influence on the dietary consumption patterns of soy for consumers and lead to the development of soy enriched foods to enable consumers to achieve the benefits thought to be associated with increased soy consumption in a Western diet. If an increase in soy consumption is beneficial to particular disease conditions, there is always the possibility that there will be effects other than those that are desirable. For soy-containing foods there has been concern that the phytoestrogen content of soy, which is composed of several isoflavones, could be a separate health issue, due to the oestrogen-like activity of isoflavones. To address this, a method has been developed to estimate, relative to 17-beta oestradiol, the activity of the common isoflavones present in soy phytoestrogens, based on their binding to and transcriptional activation of the major oestrogen receptor sub-types alpha and beta. Using this approach, the additional oestrogen-like activity that would be expected from inclusion of soy supplemented foodstuffs in a Western diet, can be determined for different sub-populations, who may have different susceptibilities to the potential for the unwanted biological effects occurring with consumption of soy enriched foods. Because of the theoretical nature of this model, and the controversy over the nature of whether some of the oestrogen-like effects of phytoestrogens are adverse, the biological effects of soy isoflavones and their potential for adverse effects in man, is also reviewed. The question that is critical to the long term safe use of foods enriched in soy is, which observed biological effects in animal studies are likely to also occur in man and whether these would have an adverse effect on human health.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14550760     DOI: 10.1016/s0273-2300(03)00091-6

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  6 in total

1.  Variation in commercial rodent diets induces disparate molecular and physiological changes in the mouse uterus.

Authors:  Haibin Wang; Susanne Tranguch; Huirong Xie; Gregory Hanley; Sanjoy K Das; Sudhansu K Dey
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-29       Impact factor: 11.205

2.  Chemoprotective activity of the isoflavones, genistein and daidzein on mutagenicity induced by direct and indirect mutagens in cultured HTC cells.

Authors:  Sandra Regina Lepri; Rodrigo Cabral Luiz; Leonardo Campos Zanelatto; Patrícia Benites Gonçalves da Silva; Daniele Sartori; Lucia Regina Ribeiro; Mario Sergio Mantovani
Journal:  Cytotechnology       Date:  2012-06-30       Impact factor: 2.058

3.  Genistein induction of human sulfotransferases in HepG2 and Caco-2 cells.

Authors:  Yue Chen; Chaoqun Huang; Tianyan Zhou; Guangping Chen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-12       Impact factor: 4.080

Review 4.  Soy, Soy Foods and Their Role in Vegetarian Diets.

Authors:  Gianluca Rizzo; Luciana Baroni
Journal:  Nutrients       Date:  2018-01-05       Impact factor: 5.717

Review 5.  Influence of sex hormones and phytoestrogens on heart disease in men and women.

Authors:  Poornima Bhupathy; Christopher Dean Haines; Leslie Anne Leinwand
Journal:  Womens Health (Lond)       Date:  2010-01

6.  Liver X receptor alpha mediated genistein induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1) in Hep G2 cells.

Authors:  Yue Chen; Shunfen Zhang; Tianyan Zhou; Chaoqun Huang; Alicia McLaughlin; Guangping Chen
Journal:  Toxicol Appl Pharmacol       Date:  2013-01-23       Impact factor: 4.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.